Skip to main content

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.

Publication ,  Journal Article
Bock, NN; Sterling, TR; Hamilton, CD; Pachucki, C; Wang, Y-C; Conwell, DS; Mosher, A; Samuels, M; Vernon, A ...
Published in: Am J Respir Crit Care Med
June 1, 2002

Once-weekly rifapentine 600 mg plus isoniazid (INH) during the continuation phase treatment of tuberculosis is associated with a relapse rate higher than that of twice-weekly rifampin plus INH. The safety and tolerability of higher rifapentine doses need to be determined. We conducted a prospective, randomized, double-blind trial of rifapentine at three doses (600, 900, and 1,200 mg) plus INH 15 mg/kg once weekly in the continuation phase treatment of culture-positive tuberculosis in 150 human immunodeficiency virus-seronegative adults. Outcome measures were discontinuation of therapy for any reason and adverse events on therapy. Treatment was discontinued in 3 of 52 (6%), 2 of 51 (4%), and 3 of 47 (6%) in the rifapentine 600-, 900-, and 1,200-mg treatment arms, respectively. Only one discontinuation, in the rifapentine 1,200-mg arm, was due to an adverse event possibly associated with study therapy. There was a trend toward more adverse events, possibly associated with study therapy, in the highest-dose arms (p = 0.051). Rifapentine 900-mg, once-weekly dosing appears to be safe and well tolerated and is being evaluated in Phase III efficacy trials of treatment of latent tuberculosis. Further evaluation of the safety and tolerability of rifapentine 1,200 mg is warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

June 1, 2002

Volume

165

Issue

11

Start / End Page

1526 / 1530

Location

United States

Related Subject Headings

  • Tuberculosis
  • Treatment Outcome
  • Rifampin
  • Respiratory System
  • Reference Values
  • Prospective Studies
  • Middle Aged
  • Male
  • Isoniazid
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bock, N. N., Sterling, T. R., Hamilton, C. D., Pachucki, C., Wang, Y.-C., Conwell, D. S., … Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia, . (2002). A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med, 165(11), 1526–1530. https://doi.org/10.1164/rccm.200201-047OC
Bock, Naomi N., Timothy R. Sterling, Carol D. Hamilton, Connie Pachucki, Yong-Cheng Wang, Donna S. Conwell, Ann Mosher, Mary Samuels, Andrew Vernon, and Andrew Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia. “A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.Am J Respir Crit Care Med 165, no. 11 (June 1, 2002): 1526–30. https://doi.org/10.1164/rccm.200201-047OC.
Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang Y-C, Conwell DS, et al. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med. 2002 Jun 1;165(11):1526–30.
Bock, Naomi N., et al. “A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.Am J Respir Crit Care Med, vol. 165, no. 11, June 2002, pp. 1526–30. Pubmed, doi:10.1164/rccm.200201-047OC.
Bock NN, Sterling TR, Hamilton CD, Pachucki C, Wang Y-C, Conwell DS, Mosher A, Samuels M, Vernon A, Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med. 2002 Jun 1;165(11):1526–1530.

Published In

Am J Respir Crit Care Med

DOI

ISSN

1073-449X

Publication Date

June 1, 2002

Volume

165

Issue

11

Start / End Page

1526 / 1530

Location

United States

Related Subject Headings

  • Tuberculosis
  • Treatment Outcome
  • Rifampin
  • Respiratory System
  • Reference Values
  • Prospective Studies
  • Middle Aged
  • Male
  • Isoniazid
  • Humans